Rock Bolting Development Site

Nextdoor Launches Developer Site to Connect Partners with the Power of Local

Retrieved on: 
Friday, December 8, 2023
Apps, Applications, Technology, Mobile, Wireless, Marketing, Advertising, Communications, Networks, Internet, Social Media, Weather, Organization, Rock Bolting Development Site, NYSE, The Weather Channel, ROI, Social, Application, The, Multimedia, API, GoFundMe, Jackson Automobile Company, Content, Microsoft, Online shopping, Nextdoor

View the full release here: https://www.businesswire.com/news/home/20231208811249/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231208811249/en/
    The Nextdoor Developer Site provides enterprises, developers, small businesses, and brands the ability to explore, access, and implement the company’s range of Application Programming Interface (API) offerings.
  • With the newly self-serve Nextdoor Ads Manager, Nextdoor CAPI also helps automate campaign management to improve scale and efficiency.
  • From recent and top neighborhood posts, to local conversations, events and marketplace listings, the Display Content APIs enable organizations to access content from Nextdoor.
  • “Nextdoor has delivered real value to partners through our content and advertising APIs,” said Heidi Andersen, Chief Revenue and Marketing Officer at Nextdoor.

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

Retrieved on: 
Monday, December 19, 2022
Cancer, Eli Lilly and Company, Rock Bolting Development Site, CSO, HDAC, Institute of Liver and Biliary Sciences, Bachelor of Pharmacy, Endometrial cancer, Biotechnology, UK Research and Innovation, Doctor of Philosophy, Trafford, Therapy, Eli Lilly, CDK, Regenerative medicine, Pharmaceutical industry, Research, Drug discovery, Growth, Novartis, Patient, Medicine, University, FDA, University of Calgary, Hebrew University of Jerusalem, Imperial College London, University of Liverpool, EMA, Survival, Ethics, Translational research, Pharmacy, Science

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company’s Board of Directors.

Key Points: 
  • NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company’s Board of Directors.
  • “It is my pleasure to welcome Peter and Trafford to our Board,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • From 2020 to present, Dr. Clarke served as a mentor to student entrepreneurs at the MIT Sandbox Innovation Fund Program.
  • Dr. Clarke has a Ph.D. in organic chemistry from Imperial College, London, and a Bachelor of Science in organic chemistry from University of Liverpool.